
Agilon Health (AGL) Stock Forecast & Price Target
Agilon Health (AGL) Analyst Ratings
Bulls say
Agilon Health Inc. demonstrated a robust financial performance in the fourth quarter, with total revenue increasing by 44.2% year-over-year, slightly exceeding projections. The company's Medicare Advantage (MA) membership grew by 36% to 527,000, supported by strong same geography growth, while improvements in medical cost data are anticipated to enhance future guidance and operational expectations. Additionally, operating expenses rose at a manageable rate, coming in below estimates, which reflects effective cost management despite the growth in membership and services.
Bears say
Agilon Health has demonstrated significant visibility issues, particularly in the second half of the year, with 2023 showcasing negative surprises in utilization forecasting that adversely impacted financial outcomes. The company reported an adjusted EBITDA of $(84.0) million for 4Q24, which was not only below expectations but also reflected a deteriorating medical margin driven by an unprofitable partnership slated for exit in 2025. Additionally, Agilon's projected decline in ACO REACH patients alongside elevated expenses related to Part D and supplemental benefits further accentuates the ongoing financial pressures facing the company, leading to a cautious outlook.
This aggregate rating is based on analysts' research of Agilon Health and is not a guaranteed prediction by Public.com or investment advice.
Agilon Health (AGL) Analyst Forecast & Price Prediction
Start investing in Agilon Health (AGL)
Order type
Buy in
Order amount
Est. shares
0 shares